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RESEARCH NOTE
Acceptability and feasibility of magnetic 
femoral nerve stimulation in older, functionally 
impaired patients
Louise A. Beveridge1,3*, Rosemary J. G. Price2, Louise A. Burton1, Miles D. Witham2, Allan D. Struthers2 
and Deepa Sumukadas2
Abstract 
Objective: Magnetic femoral nerve stimulation to test muscle function has been largely unexplored in older people. 
We assessed acceptability, feasibility, along with reproducibility and correlation with other physical function measures.
Results: Study 1 recruited older people with sarcopenia. Stimulation was performed at baseline and 2 weeks along 
with six minute walk (6MW), maximum voluntary quadriceps contraction, short physical performance battery and 
grip strength. Acceptability was measured using visual analog scales. Study 2 used baseline data from a trial of older 
people. We correlated stimulation results with 6MW, maximal voluntary contraction and muscle mass. Maximum 
quadriceps twitch tension was measured in both studies, evoked using biphasic magnetic stimulation of the femoral 
nerve. In study 1 (n = 12), magnetic stimulation was well tolerated with mean discomfort rating of 9% (range 0–40%) 
on a visual analog scale. Reproducibility was poor (intraclass correlation coefficient 0.06; p = 0.44). Study 2 (n = 64) 
showed only weak to moderate correlations for maximum quadriceps twitch tension with other measures of physi-
cal function (6 minute walk test r = 0.24, p = 0.06; maximal voluntary contraction r = 0.26; p = 0.04). We conclude that 
magnetic femoral nerve stimulation is acceptable and feasible but poorly reproducible in older, functionally impaired 
people.
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Introduction
Sarcopenia—the age-related loss of muscle mass and 
function—is a major health problem leading to increased 
disability, morbidity and mortality in older people. 
Determining the effect of interventions for sarcopenia 
in older people is challenging. Muscle function testing 
relies heavily on voluntary effort [1–3]. Magnetic nerve 
stimulation is a relatively unexplored method of objec-
tively assessing muscle function. It offers the advantage 
of measuring muscle strength and fatigability non-inva-
sively [4, 5]. Unlike exercise and many voluntary strength 
tests, magnetic nerve stimulation is performed with the 
individual rested supine and allows measurement of 
skeletal muscle function while minimising cardiovascu-
lar effort. Maximum twitch generated in the quadriceps 
through magnetic stimulation (TwQ) has been reported 
to be more reproducible and more sensitive to change 
than maximum voluntary muscle strength in some popu-
lations [6, 7] and has been used successfully in a variety of 
populations including healthy older people [8]. However 
no studies have explored magnetic femoral nerve stimu-
lation in older people with impaired physical function.
We therefore examined (a) the acceptability of mag-
netic femoral nerve stimulation in older, functionally 
impaired people, (b) the relationship between TwQ and 
other measures of muscle mass and function, and (c) the 
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Main text
Methods
Two studies are included in this report. Study 1 aimed to 
test the acceptability of magnetic femoral stimulation and 
reproducibility of TwQ in a small group of older people 
with sarcopenia; Study 2 aimed to relate magnetic femo-
ral stimulation results to a range of measures of physical 
function using baseline data from a clinical trial in older 
people with a history of falls. Both studies followed the 
principles of the declaration of Helsinki. Study 1 was 
approved by East of Scotland Research Ethics Committee 
(approval number 13/ES/0045); Study 2 was approved by 
Scotland A Research Ethics committee (approval num-
ber 13/SS/0086), and was registered as a clinical trial 
(ISRCTN58995463) with approval from the UK Medi-
cines and Healthcare Regulatory Authority (EudraCT 
number 2013-001677-24; CTA number 21726/0281/001).
Study 1
Community dwelling people > 65  years with sarcopenia 
and self-reported difficulty with one or more activities of 
daily living (ascertained by an open question to partici-
pants) were recruited through the Scottish Primary Care 
Research Network. We excluded people who had metal 
implants or metal fragments in the lower limbs, previous 
internal fixation of lower limb fracture, vascular stents, 
those with internal cardiac defibrillators, cardiac pace-
maker and implanted nerve stimulators; any condition 
(e.g. severe osteoarthritis) that was likely to be aggravated 
by lower muscle contraction; cognitive impairment pre-
cluding informed consent; inability to mobilise without 
human assistance and those residing in a nursing home.
Participants attended a baseline and follow up visit 
after 2  weeks. At the baseline visit, potential partici-
pants were screened for sarcopenia, defined as: Total 
skeletal muscle mass (SMM) measured by bioimpedance 
[9] of < 10.76 kg/m2 for men or < 6.76 kg/m2 for women 
and either low handgrip strength (< 30  kg for men or 
< 20  kg for women) or low gait speed (< 0.8  m/s for the 
4  m walk). Body composition was measured using bio-
impedance (BIA) (Akern Bodygram Pro 101 v.3.0; Akern 
Srl, Florence, Italy). The Janssen formula [10] was used 
to calculate total skeletal muscle mass/height squared 
(SMM/H2). Handgrip strength was measured in the non-
dominant hand using a Jamar dynamometer (Lafayette 
Instruments, Lafayette, Indiana, USA). The best of three 
attempts was recorded.
Outcomes
Outcomes were measured at baseline and at 2  weeks. 
Acceptability of magnetic stimulation was assessed using 
a visual analog scale, which asked participants to indi-
cate (a) the degree of discomfort whilst undertaking the 
Magstim test and (b) how tired they felt at the end of 
the study. Scales were anchored by statements, e.g. 0% 
was anchored by ‘no discomfort’ and 100% by ‘extreme 
discomfort’. The final question asked if they would have 
the magnetic stimulation test again. The time in seconds 
taken to walk 4 m at their usual pace was assessed, with 
the faster of two attempts recorded. The Short Physical 
Performance Battery (SPPB) [11] was performed accord-
ing to standard protocol. Isometric quadriceps maximum 
voluntary contraction strength (QMVC) was measured in 
a semi reclining position with the knee joint at 90 degrees 
using a Biopac tension dynamometer (Biopac Systems 
inc. California, USA). The measurement was taken on the 
right leg unless the participant had a metallic hip joint on 
this side. An inelastic strap was placed around the ankle 
and connected to the dynamometer mounted to the 
couch. The participant was then instructed to kick their 
foot out, pushing hard against the strap, hold for 10 s and 
then relax. This procedure was repeated twice. QMVC 
was taken as the highest mean force that could be sus-
tained over one second. Participants undertook a 6 min-
ute walk test along a 25 m course at their normal walking 
pace, using a walking aid if needed. Standardised encour-
agement was given. The distance covered was recorded as 
a measure of submaximal endurance.
Magnetic femoral nerve stimulation
The greatest twitch tension generated in the quadri-
ceps (TwQ) was measured using the Magstim 200 sys-
tem (Magstim Company Ltd., Whitland, UK). A double 
70 mm coil in the shape of a figure of eight was used. Par-
ticipants were placed in a semi reclining position with a 
strap around the ankle as described before. The crosso-
ver point of the coil was then positioned over the groin 
to stimulate the femoral nerve using a single biphasic 
stimulus; the femoral artery was palpated to guide place-
ment over the femoral nerve. A range of magnetic out-
puts (60, 70, 80, 90 and 3 times at 100%) were applied to 
check supramaximality of TwQ response. A 30 s interval 
was allowed between each reading.
Study 2
For study 2, we used baseline data from a double-blind 
randomised controlled trial of the effect of perindopril, 
an angiotensin converting enzyme inhibitor (ACEi) on 
postural stability in older people. Details of the inclu-
sion and exclusion criteria and study population have 
been reported previously [12]. QMVC was measured as 
described for Study 1, but fatigability was also assessed 
by performing repeated QMVC measurements with no 
break between 3  s efforts. The number of efforts per-
formed before QMVC fell to 70% of maximum was 
recorded as a measure of endurance. In addition, after 
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initial TwQ testing, three measurements at 100% were 
performed immediately and after a 10  min rest to esti-
mate the effect of fatigue and recovery on TwQ follow-
ing repeated QMVCs. Fatigability was further tested 
by measuring TwQ following the 6  minute walking test 
described above.
Statistical analysis
We used Pearson’s correlation coefficients to compare 
baseline TwQ with other baseline measures of physical 
function, and used two-way, random effects intraclass 
correlation coefficients to test reliability, comparing base-
line and follow up TwQ. All analyses were performed 
using SPSS v21 (IBM, New York, USA) and a 2-sided p 
value of < 0.05 was taken as significant for all analyses.
Results
Study 1
26 participants attended screening, of whom 12 (46%) 
proceeded to the main outcome measures. 14 (54%) had 
skeletal muscle mass above the threshold for sarcopenia 
and were not included. Details of the included partici-
pants are given in Table 1; all 12 participants successfully 
underwent magnetic femoral stimulation. After base-
line testing, the mean discomfort rating was 9% (range 
0–40%) on a visual analog scale. Mean tiredness was 
22% (range 0–71%). 11/12 (92%) undergoing magnetic 
femoral stimulation said they would be happy to undergo 
the procedure again, with one participant being unsure. 
At the second test visit, similar results were seen; mean 
discomfort 6% (range 0–18%) and mean tiredness 21% 
(range 0–79%).
Table  2 shows the reproducibility of each measure 
between the first and second visit, using all available data 
and also excluding those with a clinically significant vari-
ation in their six minute walk distance between the first 
and second visits. Given that some participants clearly 
had a change in their physical function in the 2 weeks 
between the first and second visit, we correlated the 
change TwQ with changes in the other measures of phys-
ical performance: change in QMVC r = 0.42 (p = 0.30); 
change in six minute walk distance r = 0.05 (p = 0.90); 
change in SPPB r = 0.55 (p = 0.16); change in handgrip 
r = 0.62 (p = 0.10).
Study 2
A total of 80 participants were randomised into the sec-
ond study; 68/80 (85%) agreed to have magnetic femoral 
stimulation and analysable data were available from 64/80 
(80%). Baseline details have been published previously 
Table 1 Baseline details of study 1 patients (n = 12)
MVQC maximal voluntary quadriceps contraction, TwQ quadriceps twitch tension
Baseline value Correlation with TwQ
r p
Mean age (years) (SD) 77.6 (6.2) – –
Male sex (%) 4 (33) – –
Mean height-adjusted muscle mass (kg/m2) (SD) 7.1 (1.1) 0.53 0.11
Mean 4 m gait speed (m/s) (SD) 0.65 (0.16) 0.74 0.014
Mean six minute walk distance (m) (SD) 272 (116) 0.33 0.35
Mean handgrip strength (kg) (SD) 11.1 (6.2) 0.41 0.24
Mean short physical performance battery (SD) 6.7 (2.3) 0.24 0.51
Mean MVQC (kg) (SD) 12.8 (8.9) − 0.15 0.68
Mean TwQ (kg) (SD) 1.4 (0.8) – –
Table 2 ICC (2 way, random effects model for  absolute 
agreement) between first and second visit
a Excluding those with 6 minute walk (6MW) difference of ≥ 50 m between visits
ICC (95% CI) p
6 minute walk distance
  All 0.94 (0.79–0.98) < 0.001
 Stable on  6MWa 0.98 (0.92–1.00) < 0.001
Maximal voluntary quadriceps contraction strength
 All − 0.27 (− 0.84 to 0.41) 0.77
 Stable on  6MWa − 0.63 (− 1.14 to 0.26) 0.92
Maximal quadriceps twitch tension
 All 0.06 (− 0.53 to 0.68) 0.44
 Stable on  6MWa − 0.21 (− 0.92 to 0.74) 0.65
Handgrip strength
 All 0.89 (0.65–0.97) < 0.001
 Stable on  6MWa 0.85 (0.10–0.97) < 0.001
Short physical performance battery
 All 0.55 (− 0.08 to 0.86) 0.04
 Stable on  6MWa 0.62 (− 0.13 to 0.91) 0.05
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[12]. Both mean muscle mass (7.4 [SD 1.4]kg/m2) and 
measures of muscle strength (mean MVQC 19.1 [SD 8.5] 
kg; mean TwQ 2.7 [SD 1.4] kg) were higher in study 2 
than in study 1. Table 3 gives correlations between base-
line TwQ and measures of physical function, and muscle 
mass and fat mass in the larger sample from study 2.
Discussion
Previous studies in younger populations [13, 14] have 
found that magnetic femoral nerve stimulation is feasible 
and acceptable in younger, healthy populations. How-
ever, in contrast to our results, Tofari et al. [15] demon-
strated good reliability with repeated testing, although 
testing was done more frequently and at shorter intervals 
in healthy subjects. Similarly, Vivodtzev et al. [16] dem-
onstrated high reproducibility in repeated testing on the 
same day in their study of 23 healthy sedentary partici-
pants. We noted considerable variability between visits 
for both TwQ and QMVC, and some variability between 
visits for the six minute walk distance. It is therefore pos-
sible that underlying physical function did in fact change 
in the 1–2  weeks between visits, making assessment of 
reliability more difficult. However, the ICC for magnetic 
femoral nerve stimulation was much worse than for the 
six minute walk test, SPPB or handgrip strength, sug-
gesting that notwithstanding any real changes in physical 
function, magnetic femoral stimulation measurements in 
older people have high intrinsic variability. Conversely, 
there was only moderate correlation between changes in 
TwQ and changes in other measures of physical function 
over time, suggesting that although some differences in 
TwQ between baseline and follow up may have been due 
to real changes in function, by no means all of the change 
in TwQ can be attributed to this. Poor reliability (which 
translates into a large variance around any change seen 
in studies) means that large sample sizes are likely to be 
required to detect meaningful change in clinical studies.
Our results are strengthened by using two differ-
ent, complementary study populations, one of which 
comprises older people who have sarcopenia. Previous 
studies in older patients have looked mainly at healthy 
populations with a lower mean age than seen in our 
study. Hamnegard et  al. [5] found that the mean TwQ/
QMVC ratio in younger men and women (mean age 
38 years) was 0.15. This was similar to the ratio we found 
in our older participants although the mean QMVC and 
TwQ were both much lower—18.9 versus 70.1 kg and 2.7 
versus 9.8 kg respectively. Other studies in healthy volun-
teers have shown much higher levels of muscle activation 
relative to maximal voluntary contraction however [17], 
and inability of femoral magnetic stimulation to fully 
stimulate skeletal muscle in neuropathic conditions [18] 
is a potential concern, especially given the contribution 
that denervation is postulated to make to the pathophysi-
ology of sarcopenia [19].
In conclusion, magnetic femoral nerve stimulation is 
acceptable and feasible in functionally impaired older 
people. Our results do not however support using mag-
netic femoral nerve stimulation for these patients; the 
variability of measurements, expense and cumbersome 
nature of the equipment argue against using this tech-
nique as a replacement for simple, inexpensive measures 
of physical function in current use.
Limitations
Both studies included in this report have limitations. The 
sample size were small with the main reason for failing 
screening in study 1 being muscle mass higher than the 
EWGSOP definition for sarcopenia; this limits our abil-
ity to show statistical significance for some correlations 
but does not change the point estimate for correlations. 
Participants in study 2 were not selected on the basis of 
meeting a diagnosis of sarcopenia; the higher mean six 
minute walk test values suggest that muscle function 
was not severely impaired in this participant group, and 
the generalisability of the findings from study 2 are lim-
ited by the fact that this population were highly selected 
by dint of their participation in a clinical trial. We used 
grip strength in the non-dominant hand in both studies 
for consistency as this was the measure employed in the 
clinical trial from which we obtained data, although we 
acknowledge that dominant side grip, or maximal grip 
in either hand are more commonly used [20]. A similar 
limitation applies to our use of the right leg for testing; 
Table 3 Correlations between baseline maximal Magstim response (TwQ) and measures of muscle function (n = 64)
Baseline TwQ TwQ after kicks TwQ after 6MW
r p r p r p
QMVC 0.26 0.04 0.23 0.07 0.21 0.11
6 minute walk distance 0.24 0.06 0.19 0.12 0.25 0.05
Height-adjusted muscle mass 0.17 0.20 0.19 0.14 0.17 0.19
Height-adjusted fat mass − 0.29 0.02 − 0.37 0.003 − 0.31 0.02
Number of kicks to fatigue − 0.03 0.82 − 0.06 0.64 0.06 0.63
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this was done for consistency and convenience of our 
equipment set-up, but may have led to underestimation 
of strength for participants with left leg dominance. All 
lower limb tests were however performed on the same 
leg to ensure comparability within an individual.
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